Discrepant findings in immune responses to JC virus in patients receiving natalizumab

Lancet Neurol. 2010 Jun;9(6):565-6; author reply 566-7. doi: 10.1016/S1474-4422(10)70124-1.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens / metabolism
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / therapeutic use
  • JC Virus* / metabolism
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / metabolism
  • Natalizumab
  • T-Lymphocytes / metabolism

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens
  • Immunologic Factors
  • Natalizumab
  • Interferon-beta